(NYSE: NVO) Novo Nordisk (Ozempic)'s forecast annual revenue growth rate of 15.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Novo Nordisk (Ozempic)'s revenue in 2025 is $40,559,078,212.On average, 3 Wall Street analysts forecast NVO's revenue for 2025 to be $222,072,503,595,000, with the lowest NVO revenue forecast at $218,973,690,900,000, and the highest NVO revenue forecast at $224,071,827,900,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2026 to be $254,959,313,750,000, with the lowest NVO revenue forecast at $247,246,070,900,000, and the highest NVO revenue forecast at $262,812,489,700,000.
In 2027, NVO is forecast to generate $277,446,750,450,000 in revenue, with the lowest revenue forecast at $273,983,294,600,000 and the highest revenue forecast at $280,910,206,300,000.